文献速递冠心病外科

术前氯吡格雷暴露对冠状动脉旁路移植术结局的影响

The Impact of Preoperative Clopidogrel on Outcomes After Coronary Artery Bypass Grafting.
PubMed 文献 · Ann Thorac Surg · 2019-04-27

该单中心回顾性研究纳入2010年1月至2018年2月接受孤立CABG的7048例患者,其中1240例(18%)在术前5天内使用过氯吡格雷。结果显示术前氯吡格雷暴露增加输血和因出血再手术风险,但不影响早晚期死亡率;术前停药至少3天可减轻但未消除输血风险增加。

要点

  • 术前5天内氯吡格雷暴露增加CABG后输血(53.4% vs 40.3%)和因出血再手术(3.0% vs 2.0%)风险。
  • 氯吡格雷暴露未增加未调整或风险调整的30天、1年或5年死亡率或再入院率。
  • 临床允许时CABG应延迟至少5天;更紧急情况下延迟至少3天可减轻但未消除出血风险。

核心结论

  • 近期氯吡格雷暴露患者可安全接受CABG,不增加早晚期死亡风险,但输血和再手术风险增加。
  • 临床允许时应延迟CABG至少5天,紧急情况下延迟至少3天可减轻但未消除出血风险。

研究设计与样本

  • 单中心回顾性研究,纳入2010年1月至2018年2月接受孤立CABG的7048例患者。
  • 按术前5天内是否暴露于氯吡格雷分组,暴露组1240例(18%)。
  • 主要结局为血制品输注和因出血纵隔再探查,次要结局包括早晚期死亡、主要并发症和再入院。

主要发现

  • 氯吡格雷暴露组输血率53.4% vs 40.3%(P < .001),因出血再手术率3.0% vs 2.0%(P = .02)。
  • 氯吡格雷暴露组术后卒中率2.3% vs 1.2%(P = .002),延长通气率10.2% vs 7.1%(P < .001)。
  • 氯吡格雷暴露未影响未调整或风险调整的30天、1年或5年死亡率或再入院率。
  • 术前停用氯吡格雷至少3天可减轻但未消除输血风险增加。

临床怎么用

  • 临床允许时,CABG术前应停用氯吡格雷至少5天以降低输血和再手术风险。
  • 对于指征更紧急的患者,术前停药至少3天可减轻但未消除出血风险。
  • 近期氯吡格雷暴露不应被视为CABG的禁忌,但需警惕输血和再手术风险增加。

局限性

  • 单中心回顾性研究,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated the impact of preoperative clopidogrel exposure on outcomes of coronary artery bypass grafting (CABG). METHODS: Patients undergoing isolated CABG from January 2010 to February 2018 at a single institution were included. Primary stratification was based on exposure to clopidogrel within 5 days of CABG. Primary outcomes included blood product transfusion and mediastinal reexploration for bleeding. Secondary outcomes included early and late mortality, major postoperative complications, and hospital readmissions. Multivariable Cox regression was used to evaluate the risk-adjusted impact of preoperative clopidogrel on post-CABG mortality. RESULTS: Isolated CABG was performed in 7048 patients, including 1240 (18%) who had received clopidogrel within 5 days. Patients who received preoperative clopidogrel had higher rates of transfusions (53.4% vs 40.3%, P < .001) and reoperation for bleeding (3.0% vs 2.0%, P = .02). Most postoperative complication rates were similar, although those exposed to clopidogrel had higher rates of postoperative stroke (2.3% vs 1.2%, P = .002) and prolonged ventilation (10.2% vs 7.1%, P < .001). Clopidogrel exposure did not impact unadjusted or risk-adjusted 30-day, 1-year, or 5-year mortality or readmission. Discontinuing clopidogrel for at least 3 days preoperatively mitigated but did not eliminate the increased risk of blood transfusions after CABG. CONCLUSIONS: CABG can be safely performed in patients with recent clopidogrel exposure with no increased risk of early or late mortality. However, CABG should be delayed for at least 5 days, if clinically feasible, to minimize transfusions and reoperation risk. In patients with more urgent indications, delaying CABG at least 3 days can mitigate but not eliminate the increased bleeding risk.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Seese L, Sultan I, Gleason TG, et al. The Impact of Preoperative Clopidogrel on Outcomes After Coronary Artery Bypass Grafting. Ann Thorac Surg. 2019. PMID: 31039353. doi:10.1016/j.athoracsur.2019.03.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。